SCYNEXIS INC
Close on Oct 19, 2026
- Market cap
- $43.28M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2023 Ended Dec 31, 2023 | Mar 28, 2024 | During market hours | – | – | – |
| Q3 FY2022 Ended Sep 30, 2022 | Nov 9, 2022 | Before market open | – | – | – |
| Q2 FY2022 Ended Jun 30, 2022 | Aug 15, 2022 | Before market open | – | – | – |
| Q1 FY2022 Ended Mar 31, 2022 | May 12, 2022 | During market hours | – | – | – |
| Q4 FY2021 Ended Dec 31, 2021 | Mar 29, 2022 | Before market open | – | – | – |
| Q3 FY2021 Ended Sep 30, 2021 | Nov 10, 2021 | Before market open | – | – | – |
| Q4 FY2017 Ended Dec 31, 2017 | Mar 5, 2018 | During market hours | – | – | – |
| Q3 FY2016 Ended Sep 30, 2016 | Oct 5, 2016 | During market hours | – | – | – |
Press releases
Announcements Scynexis filed with the SEC
SCYNEXIS Awarded BARDA Contract Providing Up to $214 Million in Non-Dilutive Funding for the Development of SCY-247
Material agreement · Regulation FD disclosure · EX-99.1 to Form 8-K
SCYNEXIS Appoints Seasoned Industry Veteran Steven K. Burke, M.D., to its Board of Directors
Executive or director change · Regulation FD disclosure · EX-99.1 to Form 8-K
SCYNEXIS Announces Appointment of Sanjay Subramanian as Chief Financial Officer
Executive or director change · Other events · EX-99.1 to Form 8-K
Legal Disclaimers This presentation has been prepared by SCYNEXIS, Inc.
Regulation FD disclosure · EX-99.1 to Form 8-K
SCYNEXIS Announces $40.0 million Private Placement
Material agreement · Unregistered share sale · Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
SCYNEXIS Completes Transformative Acquisition of PXL-770, an
Material agreement · Acquisition or disposition completed · Regulation FD disclosure · EX-99.1 to Form 8-K
A dynamic force in the fight against infectious disease September 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
SCYNEXIS Reports Full Year 2023 Financial Results
Results of operations · EX-99.1 to Form 8-K
A dynamic force in the fight against infectious disease January 2024
Regulation FD disclosure · EX-99.1 to Form 8-K
SCYNEXIS Reports Third Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
SCYNEXIS Reports Second Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
SCYNEXIS Reports First Quarter 2022 Financial Results
Results of operations · EX-99.1 to Form 8-K
SCYNEXIS Reports Fourth Quarter and Full Year 2021 Financial Results
Results of operations · EX-99.1 to Form 8-K
SCYNEXIS Reports Third Quarter 2021 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K